Sanara MedTech Inc. (NASDAQ:SMTI) Given Average Recommendation of "Reduce" by Analysts

Key Points

• Analysts have a consensus “Reduce” rating on Sanara MedTech, with one sell rating and four holds. The average 12-month price target is $35.00, slightly below the reported share price of $34.88.
• Institutional investors increased their positions in the company, but hedge funds and other institutions collectively own only 8.10% of outstanding shares.
• Sanara MedTech’s latest quarterly results fell short of expectations, with an adjusted loss of $0.05 per share versus the estimated $0.02 loss and revenue of $28.14 million versus the $28.95 million consensus.

Sanara MedTech Inc. (NASDAQ:SMTI - Get Free Report) has earned a consensus rating of "Reduce" from the five ratings firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $35.00.

A number of research analysts have recently issued reports on the company. Weiss Ratings upgraded Sanara MedTech from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Freedom Capital downgraded Sanara MedTech from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 3rd. Zacks Research upgraded Sanara MedTech from a "strong sell" rating to a "hold" rating in a research note on Wednesday, June 10th. Lake Street Capital downgraded shares of Sanara MedTech from a "buy" rating to a "hold" rating and set a $35.00 target price for the company. in a report on Thursday, July 30th. Finally, Wall Street Zen lowered shares of Sanara MedTech from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 1st.

Institutional Investors Weigh In On Sanara MedTech

A number of hedge funds and other institutional investors have recently bought and sold shares of SMTI. BNP Paribas Financial Markets boosted its stake in Sanara MedTech by 351.7% in the third quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company's stock valued at $48,000 after acquiring an additional 1,171 shares in the last quarter. Lazard Asset Management LLC increased its position in shares of Sanara MedTech by 63,100.0% during the second quarter. Lazard Asset Management LLC now owns 3,160 shares of the company's stock worth $89,000 after purchasing an additional 3,155 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Sanara MedTech by 44.1% during the 3rd quarter. Bank of America Corp DE now owns 3,181 shares of the company's stock valued at $101,000 after purchasing an additional 973 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in shares of Sanara MedTech by 78.1% during the 4th quarter. Wells Fargo & Company MN now owns 3,322 shares of the company's stock valued at $78,000 after purchasing an additional 1,457 shares during the last quarter. Finally, Rhumbline Advisers grew its stake in Sanara MedTech by 14.9% during the 1st quarter. Rhumbline Advisers now owns 3,714 shares of the company's stock worth $115,000 after buying an additional 483 shares during the last quarter. Hedge funds and other institutional investors own 8.10% of the company's stock.

Sanara MedTech Price Performance

NASDAQ SMTI opened at $34.88 on Tuesday. The company has a market cap of $320.55 million, a PE ratio of -9.72 and a beta of 1.12. The firm's 50 day moving average price is $29.14 and its 200-day moving average price is $23.21. The company has a debt-to-equity ratio of 5.86, a quick ratio of 2.30 and a current ratio of 2.58. Sanara MedTech has a 52-week low of $16.05 and a 52-week high of $35.95.

Sanara MedTech (NASDAQ:SMTI - Get Free Report) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.05) EPS for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.03). The business had revenue of $28.14 million during the quarter, compared to the consensus estimate of $28.95 million. Sanara MedTech had a positive return on equity of 29.72% and a negative net margin of 29.15%. Sell-side analysts forecast that Sanara MedTech will post 0.16 EPS for the current fiscal year.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company's core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source